Literature DB >> 7037069

The phenotype of the neoplastic cells of hairy cell leukemia studied with monoclonal antibodies.

J Jansen, T W LeBien, J H Kersey.   

Abstract

Eighteen cases of hairy cell leukemia were studied with a battery of polyclonal anti-Ig and nine monoclonal antibodies to determine the lineage of the hairy cells (HC) and the stage of their maturation arrest. Hairy cells tend to nonspecifically bind many antisera and precautions had to be taken to avoid nonspecific fluorescence of the cells. All but one case was reactive with one light chain type and one or more heavy chain isotype antisera as reported before. All cases studied were positive for monomorphic HLA-DR determinants, using monoclonal antibody 7.2. Most cases tested (6/7) were positive with the B-lineage related antibody PI 153/3. While most cases (15/18) were nonreactive with the B-lineage related antibody BA-1, they became positive (5/5) following in vitro culture. Seven out of nine cases were reactive with OKM1. Common acute lymphoblastic leukemia antigen (CALLA) was absent in all (15) cases tested and the ALL associated structure p24/BA-2 was absent from 16 of 18 cases. HC from none of the cases were clearly positive with the T-cell antibodies 9.6., or TA-1, whereas in only 1/18 the cells reacted with T101. The results of this study support the B cell lineage of most HC, and show the presence of multiple phenotypes. In combination with the surface Ib present on the cells, a hierarchy of phenotypes is postulated, with SIg-ormu delta, BA-1+, PI 153/3+, HLA-DR+ being the most immature, and SIg(alpha) gamma, BA-1-, PI 153/3-, HLA-DR+ the most mature.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7037069

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Hairy cell leukemia: clinical features and therapeutic advances.

Authors:  B C Lembersky; H M Golomb
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Immunoreactivity of neoplastic and non-neoplastic monocytoid B lymphocytes for DBA.44 and other antibodies.

Authors:  M Ohsawa; H Kanno; T Machii; K Aozasa
Journal:  J Clin Pathol       Date:  1994-10       Impact factor: 3.411

3.  Immunohistochemical studies of the spleen in hairy-cell leukemia.

Authors:  C J Meijer; F Albeda; P Van der Valk; P J Spaander; J Jansen
Journal:  Am J Pathol       Date:  1984-05       Impact factor: 4.307

4.  Further evidence for the B-cell nature of hairy cells. A study using immunostaining of splenic tissue with a wide panel of monoclonal antibodies.

Authors:  G Pallesen; G Kerndrup; J Ellegaard
Journal:  Blut       Date:  1984-11

5.  Crossreaction of monoclonal anti-T-cell antibodies: implications for classifying B-cell leukemias.

Authors:  R Munker; E Thiel; U Kummer; H Rodt; S Thierfelder
Journal:  Blut       Date:  1983-02

Review 6.  Immunoglobulin genes: rearrangement and translocation in human lymphoid malignancy.

Authors:  S J Korsmeyer; T A Waldmann
Journal:  J Clin Immunol       Date:  1984-01       Impact factor: 8.317

7.  Mitogenic response of neoplastic B cells: comparison of reactivity to Staphylococcus aureus Cowan I and anti-immunoglobulin antibodies.

Authors:  T Tamaki; T Yonezawa; Y Kanakura; S Katagiri; H Mizutani; T Kitani; S Tarui
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

8.  Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukaemia.

Authors:  R Foa; F Lauria; P Lusso; D Raspadori; M T Fierro; P L Tazzari; L Caudana; L Matera
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

9.  Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia.

Authors:  S J Korsmeyer; W C Greene; J Cossman; S M Hsu; J P Jensen; L M Neckers; S L Marshall; A Bakhshi; J M Depper; W J Leonard; E S Jaffe; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.